Unravelling the Mystery: Why Chronic Pain Lingers Longer in Women
Chronic pain is a pervasive and growing health concern, impacting millions worldwide. In the UK alone, an estimated 28 million people grapple with persistent discomfort, with a significant majority being women. This isn’t just a passing ache; chronic pain refers to conditions where pain lasts or recurs for over three months. While historically more prevalent in women and older individuals, new scientific insights are shedding light on a fundamental biological reason behind this disparity, particularly the prolonged nature of pain experienced by females.
Research predicts that by 2040, England’s ageing population could see an additional 2 million people suffering from chronic pain. Women, already bearing a disproportionate burden, are found to be approximately 50 per cent more likely than men to develop persistent pain. Now, experts are suggesting that chronic pain might not only be more common in women but also endure for a longer duration.
The Immune System’s Role in Pain Resolution
A groundbreaking study from Michigan State University, published in the journal Science Immunology, has identified a key factor: the differing activity levels of immune cells in men and women. The researchers concluded that women experience longer-lasting pain because their immune cells, specifically monocytes, are less active in their role of switching off pain receptors.
Professor Geoffrey Laumet, a physiologist and lead author of the study, explained the biological basis of this difference. “It’s not in your head, and you’re not soft. It’s in your immune system,” he stated, offering a crucial clarification for women experiencing persistent pain.
Monocytes are hormone-regulated immune cells responsible for deactivating pain signals. However, the research indicates that these cells are more active in men, largely due to higher levels of sex hormones like testosterone. Consequently, women, with their less active immune cells, experience prolonged pain and a delayed recovery process.
Towards Non-Opioid Pain Relief
This discovery opens exciting avenues for developing more effective pain management strategies. The researchers are hopeful they can manipulate these monocytes to produce more signals that calm pain. This could lead to more targeted relief for women suffering from chronic pain, potentially reducing reliance on opioid medications.
Understanding pain begins with how our bodies perceive it. We feel pain when neurons, normally dormant, are activated by a trigger, such as stubbing a toe. In individuals with chronic pain, these pain sensors become hypersensitive, activating more readily or even without any identifiable trigger. While acute pain typically subsides as the body heals, chronic pain involves the brain continuing to send pain signals long after the initial event. Common chronic pain conditions include backache, joint pain, headaches, migraines, and endometriosis, though it can also be diagnosed as a standalone condition.
The Challenges of Diagnosis and New Research Findings
Diagnosing chronic pain often relies on a patient’s subjective report of their pain intensity, typically on a scale of one to ten. Professor Laumet acknowledges the inherent challenge in this method, as pain perception varies significantly between individuals.
The current findings stem from early-stage animal studies. Researchers observed higher levels of a specific monocyte, interleukin-10, in male mice. Crucially, when male sex hormones were blocked, these levels decreased, leading to increased pain sensitivity in the mice. This observation led the team to conclude that “pain resolution is not a passive process. It’s an active, immune-driven one.”
These results showed a remarkable parallel with psychological outcomes studied by Professor Sarah Linnsteadt at the University of North Carolina. Her research on car accident survivors revealed that men exhibited more active interleukin-10 producing cells and recovered from pain faster than women.
Building on these insights, the research team is now exploring how treatments could target this immune pathway to enhance monocyte production and expedite pain resolution. “This work opens new avenues for non-opioid therapies aimed at preventing chronic pain before it’s established,” Professor Laumet concluded.
The Shadow of Opioids and Treatment Gaps
These findings arrive at a critical juncture, following alarming research from the previous year that questioned the effectiveness of tramadol, a widely prescribed opioid painkiller, for long-term pain relief. Despite hundreds of thousands of NHS prescriptions issued monthly for conditions like arthritis and back pain, a review of 18 studies indicated that while tramadol offered some pain reduction, the effect was often insufficient to significantly alter patients’ symptoms.
Furthermore, patients taking tramadol were found to be nearly twice as likely to experience severe side effects, including chest pain, heart disease, and heart failure, compared to those on placebo pills. The addictive nature of opioid painkillers also poses a significant problem, with addiction costing the NHS approximately £1 billion over five years.
The Royal College of Surgeons has voiced concerns that many patients are forced to depend on these potent drugs due to lengthy waiting lists for essential surgeries. This reliance, coupled with an increasing risk of addiction, is exacerbated by the current NHS situation. The health service is set to cancel tens of thousands of knee and hip replacement surgeries due to a global shortage of a vital surgical ingredient, potentially increasing the pressure on pain management strategies and the risk of opioid dependence for those awaiting procedures.
